Status:
NOT_YET_RECRUITING
Pain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
Tulavi Therapeutics,Inc.
Conditions:
Neuroma
Neuropathic Pain
Eligibility:
All Genders
22+ years
Phase:
PHASE2
Brief Summary
In 2016, one in five individuals in the United States (US) experienced chronic pain, and approximately 40% of them suffered from neuropathic pain. The physical and emotional burden on patients results...
Detailed Description
Background and Significance In 2016, one in five individuals in the United States (US) experienced chronic pain, and approximately 40% of them suffered from neuropathic pain. The physical and emotiona...
Eligibility Criteria
Inclusion
- Patients undergoing traumatic amputation of a single digit at MGB
- English-speaking
Exclusion
- Patients undergoing revision amputation or non-traumatic amputation Patients under 22 years old Patients who are pregnant and/or breastfeeding Unable or unwilling to participate in a trial study
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06915662
Start Date
April 1 2025
End Date
April 1 2027
Last Update
April 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114